Interview with Dr. Rui Tostoes | News Medical Life Sciences

Building Bridges to Scalable Allogeneic Cell Therapy

“We have two defined goals that contribute to our mission of making affordable and accessible cell therapy cures: partner with other immune cell therapy developers and develop our internal pipeline. To enable these goals, we are exploring our competitive advantage of using our proprietary molecule, IBR403, for HSC expansion in a new perfusion process, and we are continuing our work to make higher yields of the most mature NK cells possible.” – Rui Tostoes, PhD

In June 2025, ImmuneBridge participated in the 7th Annual Allogeneic Cell Therapies Summit. Our CTO, Dr. Rui Tostoes, was interviewed prior to the conference on the state of cell therapy manufacturing in general, and ImmuneBridge's work in particular. Read the full interview here.